Klineo, a French digital health startup, has secured €2 million in funding to address significant challenges within clinical trials for cancer patients. The new capital, sourced from BPI and business angels, aims to extend Klineo’s reach across France and beyond.
The funding is pivotal in addressing a critical gap in patient recruitment for clinical trials, a process that often stifles innovation in cancer therapies. With an innovative AI-driven platform, Klineo seeks to democratise access to trials that could potentially save lives.
Clinical trials provide a crucial pathway for accessing cutting-edge treatments, yet participation remains abysmally low among cancer patients. Astonishingly, over 70% of patients are willing to join trials, but fewer than 5% actually do, leading to substantial numbers of trials failing due to recruitment shortages.
The new funding allows Klineo to expand its platform to accommodate all cancer types across France by the end of 2024. The strategic plan includes a closer focus on lung cancer and aims to propel the system’s reach to new pathologies and international territories.
Bridging the Participation Gap in Clinical Trials
Founded in 2021, Klineo has established its niche in the health tech sector with an AI-based platform transforming trial accessibility. Spearheaded by a team that includes a prominent medical oncologist and top engineers, Klineo’s mission is clear: simplify the complex trial search process for both patients and doctors.
Klineo’s pilot program conducted at the Gustave Roussy Institute was a success, swiftly followed by a national initiative targeting triple-negative breast cancer. This platform exemplifies rapid and democratic access to treatment options, ensuring a larger participant pool.
AI-Based Platform Revolutionising Access
Broadening its horizon, Klineo expanded in 2023 to incorporate trials for various cancers including breast, skin, and lymphoma. The company’s growth is endorsed by numerous healthcare partners and industrial sponsors, from Pfizer to AstraZeneca.
Support from critical stakeholders such as BPI, the Pfizer Healthcare Hub, and PariSanté Campus has fortified Klineo’s platform. These collaborations infuse both credibility and vitality into its ongoing development, propelling the mission to connect patients with viable, existing clinical trials.
Collaborative Efforts and Expanded Cancer Trials
Klineo’s co-founder Dr Arnaud Bayle highlights the strenuous process cancer patients face in finding suitable trials. “Today, too few patients benefit from clinical trials; the search is tedious,” he asserts. Klineo addresses this issue with its user-friendly, swift trial-matching solution, which places patients in contact with relevant trials in minutes.
CEO Thomas Peyresblanques adds, “Our investors’ trust underlines the crucial nature of our mission: assuring fair trial access.” The funding is expected to expedite the inclusion of diverse patient groups in essential research.
Strategic Insights from Leadership
With plans to expand into Europe and the USA, Klineo sets its sights on rare and neurological diseases as future domains. This expansion is a leap in bridging current geographic and scientific barriers in trial accessibility.
Klineo’s commitment to enhancing its technological platform aligns with its strategic goal of international reach. The €2 million funding is not merely an investment but a stepping stone towards redefining global clinical trial methodologies.
Global Expansion Plans
Klineo’s influence extends beyond individual patient support; it impacts broader medical research advancements. By facilitating fair access to trials, Klineo enriches scientific research and accelerates treatment innovation, benefitting both the medical community and patients.
This initiative showcases how technology can transform traditional processes, setting a precedent for future ventures in medical trial accessibility.
Redefining Medical Research Accessibility
Klineo’s pioneering efforts showcase a crucial intersection of technology and medicine, offering hope to cancer patients and the healthcare industry alike. As the company advances, it not only promises enhanced patient engagement but also invigorates the broader clinical research landscape.
Impact on Healthcare and Future Prospects
Klineo continues to demonstrate a pivotal role in transforming the landscape of clinical trials with its innovative platform. The latest funding will not only bolster its presence across cancer treatment fields but also globally, bridging significant gaps in clinical trial access.
The commitment to removing barriers and accelerating research inclusion is a promising stride towards more equitable healthcare solutions worldwide.
